Sick Economics. Healthcare Investing Tips & Analysis. Big Pharma, Biotech, Medical Devices, Healthcare REITs & More.
Our favorite biotech shares and healthcare investments in today’s stock market. Highlighting companies that stand to profit through medical innovation, mismatches in share price to market potential, or just plain great economics. (Stocks may be owned by the Sick Economist, or other commentators on this page.)
In 2019, ADMA acquired a manufacturing facility to ensure better quality control of its formulations for patients with immune deficiencies. ADMA is now emerging from a period of intense investment in its infrastructure. The company is now growing revenue by manufacturing and marketing blood plasma products, including Ascensiv, a plasma therapy for patients who suffer from Primary Humoral Immunodeficiency. In the first half of the 2020, the company grew its revenue by 78%, to $18 million. ADMA aims to grow revenues exponentially, forecasting $250 million in revenue within the next five years.
This Australian company, listed on the NASDAQ stock exchange, seeks to treat a wide range of diseases through the creation of new kinds of cellular therapies. MESO currently has three phase III products in development. On August 14th, 2020, an FDA advisory committee voted 9-1 to recommend approval of Remestemcel-L as a novel treatment for graft vrs host disease in children. This vote puts Meso on track to launch its first FDA approved product in 2021. The company is also in advanced testing of new cellular therapies for severe Covid-19, lower back pain, and cardiovascular disease.
Morphic Holding, Inc, is pioneering therapies that focus on integrins, a category of proteins that play a role in many chronic diseases of the autoimmune, cardiovascular and metabolic systems. The small biotech has recently expanded on a partnership with a Pharma Giant (ABBV). AbbVie has chosen to exercise a license option to develop Morphic’s αvβ6 integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications. We’ll be keeping a close eye on MORF over the coming months and years. If all goes well, MORF has a massive potential upside.